Black Hawk Acquisition Corporation Class A (BKHA)
NASDAQ: BKHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BKHA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.68M
- P/E (TTM)
- 5.61
- EPS (TTM)
- $0.33
- Dividend yield
- None
- 52-week range
- 1.75 – 23.00
- Day range
- 1.75 – 2.39
- Volume / Avg
- 2.13M / 101.40K
- Beta
- —
- Shares outstanding
- 4.15M
52-week range
BKHA stock today
On Nov 20, BKHA ended the session at $1.85, shedding $4.63 (71.45%), versus the S&P 500's 3.70% decline. Volume was 21.0x the average at 2.13M shares, a sign of unusually heavy trading. At this level, BKHA sits near the bottom of its 52-week range of $1.75 to $23.00: 92.0% below the high, set on Oct 12, 2026 and 5.7% above the low.
Black Hawk Acquisition trades at 5.6x its trailing twelve-month earnings per share of $0.33.
Summary generated from market data by MetaCap's automated system. Methodology
About Black Hawk Acquisition
Company profileBlack Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Kent Louis Kaufman
- Headquarters
- Danville, CA
- IPO year
- 2024
- Website
- bhspac.com
Financial highlights
Full financialsNet income was $1.3 million (-30.6% year over year).
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | — | — |
| Growth | — | — |
| Net income | $1.33M | $1.92M |
| EPS (diluted) | — | — |
Black Hawk Acquisition peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALGSAligos Therapeutics Inc. | 1.22 | -2.40% | $7.62M | vs BKHA |
| INTSIntensity Therapeutics Inc. | 2.48 | -2.36% | $8.19M | vs BKHA |
| INABIN8bio Inc. | 0.758 | -1.86% | $8.19M | vs BKHA |
| JSPRJasper Therapeutics Inc. | 8.69 | -18.25% | $9.64M | vs BKHA |
| ATYRaTyr Pharma Inc. | 3.82 | +3.52% | $9.74M | vs BKHA |
| TCRXTScan Therapeutics Inc. | 0.1459 | +2.24% | $9.89M | vs BKHA |
| VIVSVivoSim Labs Inc. | 0.2608 | -10.53% | $5.29M | vs BKHA |
| SNTISenti Biosciences Holdings Inc. | 1.77 | -36.56% | $4.60M | vs BKHA |
Indexes, lists and sector
Black Hawk Acquisition stock FAQ
What is Black Hawk Acquisition's stock price today?
BKHA last traded at $1.85 as of Nov 20, 4:00 PM EST, down 71.45% on the day. Prices are delayed at least 15 minutes.
What is BKHA's P/E ratio?
BKHA trades at a trailing P/E ratio of 5.61.
Who is Black Hawk Acquisition's CEO?
Mr. Kent Louis Kaufman is the chief executive officer of Black Hawk Acquisition Corporation Class A.
What is the BKHA 52-week high?
The 52-week high for BKHA is $23.00 and the 52-week low is $1.75. The stock is currently 92.0% below its high.